SEC Tracker
Get the app

Mirum Pharmaceuticals MIRM

Mirum Pharmaceuticals announces positive results from PROGRESS Cohort 2

Item 8.01 Other events

Form
8-K
Filed
Importance
Routine
  1. Zilurgisertib reduced total HO lesion volume by 8.09 cm at Week 24.
  2. No zilurgisertib-treated patients developed new HO lesions.
  3. Cohort 2 included 25 pediatric patients aged 6 to <12 years with FOP.
  4. CAJIS scores improved by 0.80 points in zilurgisertib group.

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Mirum Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Acadia Pharmaceuticals ACAD public float $2.3B, Jun 30, 2025
  2. Twist Bioscience TWST public float $2.3B, Mar 31, 2025, over 18 months old
  3. Xenon Pharmaceuticals XENE public float $2.4B, Jun 30, 2025
  4. Summit Therapeutics SMMT public float $2.5B, Jun 30, 2025
  5. Cytokinetics CYTK public float $2.5B, Jun 30, 2025